There’s a big market for new treatments for TB, malaria and other ailments. But most of these diseases afflict low-income people unable to pay for medicine.
Treatment for drug-resistant TB remains problematic as the painful daily injectable patients receive for at least six months leaves more than 60% deaf.
The health care debate in the US has focused on a looming crisis, with millions possibly losing insurance coverage. In India, an immediate crisis looms with tuberculosis.